



#15
On 09/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent

In re patent application of: CHELLY et al.

Serial No.: 09/581,422

Examiner: Sisson

Filed: June 13, 2000

Art Unit: 1634

For: A NEW GENE CALLED OLIGOPHRENIN 1, ITS...

Atty. Docket No.:

P06780US0/BAS

RESPONSE TO NOTICE TO COMPLY WITH
SEQUENCE LISTING REQUIREMENTS

RECEIVED

Honorable Commissioner for Patents

SEP 11 2002

Washington, D.C. 20231

TECH CENTER 1600/2900

SIR:

In response to the Notice to Comply with Sequence Listing requirements dated August 26, 2002, please amend the above-identified application as follows:

IN THE SPECIFICATION:

After page 30, please substitute the attached sequence listing for the one previously filed.

REMARKS

In response to the Notice to Comply with sequence listing requirements, Applicants now provide a sequence listing which overcomes the objections.

STATEMENT


Applicant states in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicants submit that this case is now in compliance with sequence listing regulations, and examination and allowance of the present case is respectfully requested. Should there be any additional requirements with regard to the Sequence Listings, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

September 6, 2002

LARSON & TAYLOR, PLC
1199 North Fairfax Street, Suite 900
Alexandria, Virginia 22314
(703) 739-4900


B. Aaron Schulman
Registration No. 31,877



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent

In re patent application of: CHELLY et al.

Serial No.: 09/581,422

Examiner: Sisson

Filed: June 13, 2000

Art Unit: 1634

For: A NEW GENE CALLED OLIGOPHRENIN 1, ITS
EXPRESSION PRODUCT, AND THE...

Docket No: P06780US0/BAS

RESPONSE TO NOTICE TO COMPLY

RECEIVED

Commissioner for Patents
Washington, D.C.

SEP 11 2002

TECH CENTER 1600/2900

S I R:

In response to the Notice to Comply with Sequence Requirements mailed August 26, 2002, enclosed are the following:

- ☒ **Copy of Notice to Comply With Sequence Listing Requirements**
- ☐ **Declaration** signed by the named inventor(s)
- ☐ **Application Data Sheet** supplementing signed declaration
- ☐ Accurate English **translation** of the application
- ☐ **Check** for \$ _ (as calculated below)
- ☐ Recordation Form Cover Sheet and **Assignment** document to be recorded
- ☐ Certified copy of **Priority Document**, the priority of which is hereby claimed
- ☐ **Preliminary Amendment** reducing the filing fee.
- ☐ Information Disclosure Statement
- ☒ Other: Response to Notice to Comply with Sequence Listing Requirements;
Sequence Listing; Diskette

Fee Calculation (after reducing filing fee by preliminary amendment if noted above).

Note: Applicant claims **small entity status**

FEE CALCULATION and notations					
	Now	Basic Number	Present Extra	Rate	\$
..... TOTAL CLAIMS		- 20		X \$ 18 =	
..... INDEP. CLAIMS		- 3		X \$ 84 =	
..... MULTIPLE DEPENDENT CLAIM(S)				+ \$ 280 =	
..... LATE FILING SURCHARGE				+ \$ 130 =	
.....				BASIC FEE \$ 740 =	
TOTAL OF ABOVE CALCULATIONS =					
..... Reduction by ½ for small entity status of applicant				-	
SUBTOTAL =					
..... Fee for recording of assignment				+ \$ 40 =	
..... Fee for non-English specification				+ \$ 130 =	
TOTAL OF ALL FEES =					-0-

☒ If no check or an insufficient check is enclosed and a fee is due in connection herewith, the Commissioner is authorized to charge any fee or additional fee due in connection herewith to Deposit Account No. 12-0555.

Respectfully submitted,

Date: 6 September 2002

By: B. Aaron Schulman
Reg. No.: 31,877

LARSON & TAYLOR, PLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314



Notice to Comply

Application No.

09/581,422

Examiner

Bradley L. Sisson

Applicant(s)

CHELLY ET AL.

Art Unit

1634

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED

SEP 11 2002

TECH CENTER 1600/2900